Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

Bosutinib Impurity 35

Bosutinib Impurity 35 is listed in the pharmaceutical impurity collection under CAS 1307530-78-4. Its represented structure has formula C10H9ClN2O2 and a calculated molecular weight of 224.65 g/mol.

2D chemical structure

O C l N H O N

Chemical identity

Catalog name
Bosutinib Impurity 35
Common name
Bosutinib Impurity 35
Chemical name
N-(2-chloro-5-methoxyphenyl)-2-cyanoacetamide
CAS
1307530-78-4
SMILES
COc1ccc(Cl)c(NC(=O)CC#N)c1
InChI
InChI=1S/C10H9ClN2O2/c1-15-7-2-3-8(11)9(6-7)13-10(14)4-5-12/h2-3,6H,4H2,1H3,(H,13,14)
InChIKey
RPOVXNIHRQRBMI-UHFFFAOYSA-N
Associated API
Bosutinib

Record ID: Af9c4bc4ffbee

Computed properties

C10H9ClN2O2 Molecular formula
224.647 g/molMolecular weight
224.0353 DaMonoisotopic exact mass
62.12 ŲTopological polar surface area
2.2008 Calculated LogP (Wildman–Crippen)
56.8637 cm³/molMolar refractivity (Wildman–Crippen)
3 countHydrogen-bond acceptors
1 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 1 2 3 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C Cl H N O 0 3 6 9 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight224.64723.74
Calculated LogP (Wildman–Crippen)2.200846.35
Topological polar surface area62.1242.68
Hydrogen-bond acceptors333.13
Hydrogen-bond donors138.08
Rotatable bonds (strict)337.08

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC10H9ClN2O2dimensionless
Molecular weight224.647g/mol
Monoisotopic exact mass224.0353Da
Topological polar surface area62.12Ų
Calculated LogP (Wildman–Crippen)2.2008dimensionless
Molar refractivity (Wildman–Crippen)56.8637cm³/mol
Hydrogen-bond acceptors3count
Hydrogen-bond donors1count
Rotatable bonds (strict)3count
Heavy atoms15count
Heteroatoms5count
Rings1count
Aromatic rings1count
Aliphatic rings0count
Saturated rings0count
Aromatic heterocycles0count
Aliphatic heterocycles0count
Saturated heterocycles0count
Aromatic carbocycles1count
Aliphatic carbocycles0count
Fraction of sp³ carbon atoms0.2fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters0count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area92.4119Ų
Valence electrons78count
Radical electrons0count
Bertz complexity412.3737index
Balaban J2.8421index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for Bosutinib Impurity 35

Qualification and safety assessment of Bosutinib Impurity 35

Explore toxicological qualification of Bosutinib Impurity 35 and ICH M7 mutagenic impurity assessment of Bosutinib Impurity 35 for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for Bosutinib Impurity 35 and acceptable intake and limit justification for Bosutinib Impurity 35. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for Bosutinib Impurity 35

Explore Altox services and software through the Altox Pharma-Hub.